Ataxia clinical trials

Explore recruiting ataxia clinical trials.

Recruiting ataxia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ataxia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study

Italy, Germany, Austria, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis

France, Portugal, Germany, Italy, Spain, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1

Italy, Poland, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

Spain, Portugal, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Telangiectasia.

Poland, Norway, Denmark, Germany, Spain, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study of EryDex in Patients with Ataxia-Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)

Denmark, Norway, Germany, Italy, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ataxia trials by city

Ataxia in Toronto Ataxia in Vancouver Ataxia in Montreal Ataxia in Calgary Ataxia in Edmonton Ataxia in Ottawa Ataxia in Winnipeg Ataxia in Quebec City Ataxia in Hamilton Ataxia in Kitchener Ataxia in London Ataxia in Halifax Ataxia in New York Ataxia in Los Angeles Ataxia in Chicago Ataxia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease